Objective-In cultured human vascular smooth muscle cells, insulin increases cyclic GMP production by inducing nitric oxide (NO) synthesis. The aim of the present study was to determine whether in these cells the insulin-stimulated NO/cyclic GMP pathway plays a role in the regulation of glucose uptake. Methods and Results-Glucose transport in human vascular smooth muscle cells was measured as uptake of 2-deoxy-D-[ 3 H]glucose, cyclic GMP synthesis was checked by radioimmunoassay, and GLUT4 recruitment into the plasma membrane was determined by immunofluorescence. Insulin-stimulated glucose transport and GLUT4 recruitment were blocked by an inhibitor of NO synthesis and mimicked by NO-releasing drugs. Insulin-and NO-elicited glucose uptake were blocked by inhibitors of soluble guanylate cyclase and cyclic GMP-dependent protein kinase; furthermore, glucose transport was stimulated by an analog of cyclic GMP. Conclusions-Our results suggest that insulin-elicited glucose transport (and the corresponding GLUT4 recruitment into the plasma membrane) in human vascular smooth muscle cells is mediated by an increased synthesis of NO, which stimulates the production of cyclic GMP and the subsequent activation of a cyclic GMP-dependent protein kinase.
I nsulin-stimulated glucose uptake is primarily mediated by the facilitative transporter GLUT4, which after hormonal stimulation is recruited from intracellular membranes to the cell surface, resulting in an enhanced glucose uptake (for review see Foster and Klip 1 ). The precise mechanism by which insulin directs exocytosis of GLUT4-containing vesicles in different cell types has not been completely clarified. Multiple studies have suggested a necessary role of the insulin receptor-catalyzed tyrosine phosphorylation of insulin receptor substrate proteins and the subsequent activation of the p85/p110-type phosphatidylinositol 3-kinase (PI-3K). 2 However, several lines of evidence suggest that insulin must generate additional and possibly separate signals to increase glucose transport, such as the activation of the small GTPase TC10, 3 and the rearrangement of the microtubule-and actinbased cytoskeleton. 4, 5 Another cell signaling pathway that appears to markedly stimulate glucose uptake in skeletal muscle involves the nitric oxide (NO)/cyclic GMP (cGMP) pathway. NO stimulates glucose transport in isolated skeletal muscles and mediates in vivo exercise-induced glucose transport: 6 -8 part of the in vivo mechanism involves the release of NO from the endothelium, causing enhanced blood flow and glucose delivery to the muscle. 9 -11 Recent data suggest that NO elicits glucose uptake in skeletal muscle through the activation of an AMP-activated protein kinase (AMPK), a mechanism that is distinct from both insulin and contraction signaling pathways. 12, 13 It is known that insulin has vasodilator actions in vivo that depend on endothelium-derived NO. 14, 15 Indeed, insulin stimulates production of NO in human endothelial cells in vitro, 16 and the insulin receptor tyrosine kinase, PI-3K, and Akt all play significant roles in insulin-dependent production of NO in endothelium. 17 It has been proposed that insulin-induced vasodilation is mediated, at least in part, by the stimulation of endothelial NO production, causing inhibition of contraction of the underlying vascular smooth muscle cells (VSMCs) via activation of the VSMC guanylate cyclase (GC). The relaxant effect exerted by insulin in VSMCs is not necessarily mediated by endothelial cells only. Actually, a direct effect of insulin on cultured VSMCs has been observed in vitro, showing that these cells are target of insulin action (for review, see Trovati and Anfossi 18 ). Indeed, insulin elicits antiapoptotic signaling in VSMCs by inducing rapid tyrosine phosphorylation of the insulin receptor and IRS-1, followed by a 3-fold increase of IRS-1-bound PI-3K and a robust enhancement of Akt-3 phosphorylation and activity downstream of PI-3K. 19, 20 In addition, it has been reported that in cultured VSMCs, insulin increases (1) cGMP production via a NO-dependent mechanism 21 and (2) inducible NOS expression and cGMP generation via the PI-3K pathway. 22 We recently demonstrated that human VSMCs (hVSMCs) express an endothelial-type, calcium/calmodulin-dependent NO synthase (NOS) and exhibit an increased production of both NO and cGMP in response to the calcium ionophore ionomycin. 23 Insulin stimulates hVSMC calcium-dependent NOS activity in a few minutes, and insulin-induced NO and cGMP production is completely blunted by the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME). 23 The aim of the present study was to determine whether in hVSMC insulin-derived NO plays any role in the regulation of one of the most important effects of insulin, ie, its ability to increase the rate of cellular glucose transport. We additionally investigated which signaling events are required for NO to act as a regulator of insulin-mediated glucose uptake.
Methods

Materials
Dulbecco's modified Eagle's medium (DMEM), FCS, and other tissue culture products were obtained from GIBCO BRL; plastic for cell culture was from Falcon (Becton Dickinson). 
Cell Cultures
Experiments were done with hVSMCs derived from microarterioles obtained from male patients, 45 to 55 years old, undergoing abdominal surgery because they were affected by gallbladder stones without inflammatory processes. Isolation and characterization were made according to classical procedures 24 ; ie, cells were characterized by phenotype and checked for the presence of the smooth muscle isoform of ␣-actin and the absence of factor VIII. Cells retained differentiated properties even after multiple passages. Cells were cultured in a 5% CO 2 atmosphere at 37°C by using DMEM supplemented with 10% FCS, and were buffered with 10 mmol/L N-Tris (hydroxymethyl) methyl-2-aminoethane-sulfonic acid and 10 mmol/L HEPES. For the experiments, cells were used at the fourth to sixth passage and cultured in 35-or 100-mm-diameter Petri dishes until 75% confluence was achieved; then the medium with serum was removed, and cells were made quiescent by serum starvation and culture in DMEM containing 0.1% (w/v) bovine serum albumin (DMEM/BSA). After a 24-hour quiescence, the medium was removed, and fresh DMEM/BSA was added to the cell layer. Measurements were performed after incubation of hVSMCs in the presence of different agonists (including the NO donors), with and without coincubation with different inhibitors.
Aerobic Consumption of Glucose
After a 45-minute incubation in the absence or presence of NO donors, the cells were washed, detached, and checked for the rate of mitochondrial respiration by measuring 14 CO 2 evolution from [6-14 C]glucose, as previously described. 25 
Glucose Transport Assay
At the end of the different incubation periods in the presence of agonists and/or inhibitors, cells were rinsed once with glucose-free HEPES-buffered saline solution (mmol/L: 140 NaCl, 20 HEPES/Na, 5 KCl, 2.5 MgSO 4 , and 1 CaCl 2 at pH 7.4) and were subsequently incubated in the same buffer for 8 minutes with 10 mol/L 2-deoxy-D-glucose containing 0.3 Ci/mL 2-deoxy-D-[ 3 H]glucose. Under these conditions the glucose uptake was linear for at least 20 minutes (data not shown). Uptake was stopped by rapid removal of the buffer, followed by 3 washes in ice-cold PBS. Cells were disrupted by adding 50 mmol/L NaOH, and the radioactivity associated with the cells was determined by scintillation counting. Protein concentrations were determined by the BCA kit from Pierce, and the uptake was expressed in pmol 2-deoxy-Dglucose ⅐ min Ϫ1 ⅐ mg Ϫ1 cell protein. Uptake values were corrected for the noncarrier-mediated transport by measuring hexose uptake in the presence of 10 mol/L cytochalasin B (a potent inhibitor of facilitated glucose transport). The nonspecific association of deoxyglucose with the cells was typically Ͻ10% of the total uptake.
cGMP Determination
At the end of a 45-minute incubation in 35-mm Petri dishes in the presence of agonists and/or inhibitors, the medium was removed, and 300 L of absolute ethanol was added to make the cells permeable. After ethanol was completely evaporated, 300 L of Tris-EDTA buffer (50 mmol/L Tris-HCl, 4 mmol/L EDTA at pH 7.5) was added to each dish. After a 10-minute equilibration period, 100 L of supernatant was tested for the cGMP level with a [ 3 H]cGMP assay kit provided by Immuno Biological Laboratories, and the results were expressed as picomoles cGMP per milligram cell proteins. For the cGMP assay, the discrimination was 0.05 pmol/mL, and the cross-reactivity with cAMP was Ͻ0.001%.
Western Blot Analysis
Cells were directly solubilized in boiling Laemmli buffer containing the protease inhibitor cocktail set III (mmol/L: 100 AEBSF, 0.08 aprotinin, 5 bestatin, 1.5 E-64, 2 leupeptin, and 1 pepstatin; Calbiochem-Novabiochem Corporation), and proteins, separated by SDS-PAGE (12%), were transferred to polyvinylidene difluoride filter membrane (Immobilon P, Millipore) and probed with rabbit polyclonal antibodies (diluted 1:500 in PBS-BSA 1%) anti-human GLUT4 (Santa Cruz Biotechnology; catalog no. sc-7938) and antihuman cGMP-dependent protein kinase (PKG) I␣ (Calbiochem, VWR International; catalog no. 370652), or with the mouse monoclonal antibody 16C2 (1:2000), specific for vasodilator-stimulated phosphoprotein (VASP) phosphorylated at serine 239 (Upstate, D.B.A.; catalog no. 05-611). 26 After an overnight incubation, the membrane was washed with PBS-Tween 0.1% and subjected to a peroxidase-conjugated antibody (diluted 1:1000 in PBS-Tween with Blocker nonfat dry milk 5%, Bio-Rad) anti-rabbit or anti-mouse IgG (donkey; Amersham International; catalog no. NA934V and NA931V). The polyvinylidene diflouride membrane was washed again with PBS-Tween, and proteins were detected by enhanced chemiluminescence (Amersham International).
Immunofluorescence Studies
Cells were grown on polylysine-coated glass coverslips. At the end of the different incubation periods in the presence of agonists and/or inhibitors, cells were fixed in paraformaldehyde/sucrose fixing solution (3% paraformaldehyde, 4% sucrose in PBS at pH 7.4, for 20 minutes at room temperature), blocked in 1.5% normal goat serum, and incubated overnight at 4°C with anti-GLUT4 polyclonal antibodies (1:250 dilution) without a permeabilization step, in order to analyze the fluorescence associated with the cell surface only. Afterward, cells were treated with biotinylated anti-mouse IgG2a (Vector; catalog no. BA2001) followed by fluorescein-avidin D, and mounted. Staining was observed with an Olympus IX-70 inverted confocal laser scanning microscope equipped with a Crypton-Argon ion laser (488/568 nm). All images were taken with the same scanning setting, and fluorescence intensity average of each image was quantified by Scion Image Software (Scion Corporation) in 20 randomly chosen cellular fields. Fluorescence intensity was expressed as arbitrary units and plotted as a graph.
Statistical Analysis
All data in text and figures are provided as meanϮSEM. Statistical analysis has been carried out by means of Student's t test.
Results
Insulin Stimulates Glucose Transport and a Rapid Increase of GLUT4 at the Cell Surface in hVSMCs: Both Are Mediated by NO
hVSMCs were incubated with different concentrations of insulin for 45 minutes before the assay of 2-deoxy-D-glucose transport (Figure 1, left) , and with 100 nmol/L insulin for different time periods up to 1 hour (Figure 1 , right). Maximal stimulation of 2-deoxy-D-glucose uptake, corresponding to an Ϸ1.7to 1.8-fold increase over basal, was achieved after a 45-minute exposure to 100 nmol/L insulin: this experimental condition was then used in the subsequent experiments. Cytochalasin B decreased basal glucose uptake by Ͼ90% (data not shown), which confirmed that glucose uptake resulted from a specific carrier-mediated transport.
To investigate the role of NO in insulin-stimulated glucose transport, hVSMCs were incubated with insulin in the presence of the NOS inhibitor L-NAME, which completely abolished the insulin-mediated 2-deoxy-D-glucose uptake (Figure 2) . Moreover, the NO donor GS-NO elicited a 2-fold increase in 2-deoxy-D-glucose uptake (Figure 2) . A similar effect was evoked by SNP ( Figure 2 ). As the mitochondrion has been proposed to be one of the primary cellular targets of the cytotoxic action of NO (for review see Wink and Mitchell 27 ) , after exposure to GS-NO and SNP, the cells were checked for the rate of mitochondrial respiration by measuring 14 CO 2 evolution from [6-14 C]glucose. 25 The amount of 14 The immunoblotting with a specific anti-GLUT4 antibody demonstrated that the hVSMCs used in the present study expressed this glucose transporter isoform (data not shown).
To check whether insulin and NO increase the GLUT4 translocation at the plasma membrane, we performed confocal microscopy analysis of the transporter localization without permeabilization in order to stain the cell surface only. In the absence of insulin, few transporter molecules were detected on the cell surface; after brief exposure to insulin, the GLUT4 content of the plasma membrane increased (Figure 3) 3.3-fold. The incubation with insulin in the presence of the NOS inhibitor L-NAME reverted the insulin effect ( Figure 3) . The NO donor GS-NO exerted a remarkable insulin-like effect on GLUT4 subcellular distribution (3.9-fold increase in the plasma membrane), which was not influenced by L-NAME coincubation (Figure 3 ).
GC and PKG Are Involved in the Insulin-Stimulated Glucose Transport of hVSMCs
When the cells were incubated with insulin in the presence of ODQ, a selective inhibitor of soluble GC (sGC), the insulinstimulated 2-deoxy-D-glucose uptake was abolished ( Figure  4) . The inhibitory effect of ODQ was reversed by the coincubation with the membrane permeable cGMP analog 8-Br-cGMP (Figure 4) , which, per se, was a potent inducer of 2-deoxy-D-glucose uptake (Figure 4 ). Also the GS-NOelicited 2-deoxy-D-glucose uptake was inhibited by ODQ ( Figure 4) . We had already shown 23 that in hVSMCs, insulin induces a NO-dependent cGMP increase. The stimulating effect of insulin on the cGMP intracellular concentration ( Figure 5 ) was mimicked by SNP and GS-NO ( Figure 5 ). In Figure 1 . Left, hVSMCs were incubated with insulin at the concentrations shown for 45 minutes, and 2-deoxy-D-glucose transport was assayed as described in the Methods section. Right, hVSMCs were stimulated with 100 nmol/L insulin for various periods of time before assay of 2-deoxy-D-glucose transport. Data are presented as meanϮSEM (nϭ8). *PϽ0.05 vs basal value (0); **PϽ0.005 vs basal value (0). keeping with the observations on glucose transport (Figure 4) , the insulin-, SNP-and GS-NO-induced cGMP increase was completely inhibited by ODQ ( Figure 5 ). When hVSMCs were incubated with insulin in the presence of Rp-8-Br-cGMPS, a selective inhibitor of PKG, the insulin-stimulated 2-deoxy-D-glucose uptake was abolished ( Figure 6, top) . The inhibitor blocked also the activating effect of 8-Br-cGMP on 2-deoxy-D-glucose uptake (Figure 6 , top). The incubation with the PKG inhibitor also resulted in a significant reduction of basal 2-deoxy-D-glucose transport (Figure 6, top) . hVSMCs expressed predominantly PKG I␣, as checked by Western blotting experiments (data not shown). So far, we looked for a direct measurement of PKG activation elicited by insulin, NO donor, and cGMP analog in hVSMCs. The functional effects of PKG are thought to be owing to the phosphorylation of specific target proteins, including VASP, the 46/50-kDa vasodilator-stimulatedphosphoprotein, which is expressed in VSMCs and phosphorylated at serine 239 by PKG. 26, 28 VASP phosphorylation at serine 239, measured with the monoclonal antibody 16C2, 
Discussion
VSMCs have been shown to express the insulin-responsive glucose transporter GLUT4 29 -31 and exhibit a significant insulin-responsive glucose uptake, 32, 33 similar to that of skeletal muscle and adipose tissue. In most GLUT4expressing tissues (eg, heart muscle, skeletal muscle, fat), the great majority of GLUT4 molecules reside within an intracellular vesicular compartment until the cells are stimulated by insulin, at which time they are translocated and inserted into the plasma membrane, where they mediate glucose uptake. 1 Because insulin is known to act as a potent vasodilator 14 -17 and to increase NO production in VSMCs, 21, 23 we examined the contribution of the NO signaling pathway in insulin-mediated glucose transport and GLUT4 translocation in hVSMCs.
The results of the present study indicate that insulin stimulates glucose transport and GLUT4 translocation in hVSMCs owing to its ability to increase endogenous NO production via activation of NOS, as the NOS inhibitor L-NAME completely blocks both insulin-mediated effects. In addition, different NO donors (GS-NO and SNP) behave as insulin mimetics and effectively enhance both glucose transport and GLUT4 translocation in hVSMCs, bypassing the inhibitory effect of L-NAME. These results suggest that in hVSMCs, NO plays an important role in both insulindependent relaxation/vasodilation and glucose uptake. VSMCs have metabolic properties that make them peculiarly sensitive to glucose transporter expression and activity: glucose transport is rate-limiting for glucose metabolism in VSMCs, 34 as GLUT4 is nearly or completely saturated at most physiological concentrations of glucose. 35 To understand further the mechanism whereby NO regulates insulin-mediated glucose transport in hVSMCs, we examined the contribution of GC and cGMP in the insulin effect. NO is known to activate sGC, which is the predominant intracellular NO receptor in VSMCs (for review, see Lincoln and Cornwell 36 ), leading to increased levels of cGMP. We have already shown 23 that in hVSMCs, insulin induces a significant enhancement of NO production and a NO-dependent cGMP increase. Our present results show that ODQ, which renders sGC insensitive to activation by NO, 37 abolishes the insulin-and the GS-NO-stimulated glucose uptake, and the insulin-, SNP-and GS-NO-induced cGMP increase. So far, both insulin and NO donors require NOdependent cGMP production to stimulate glucose transport in hVSMC. Indeed, the membrane permeable cGMP analog 8-Br-cGMP reverses the ODQ inhibitory effect and is a potent inducer of glucose uptake per se.
Our results suggest that the role of NO/cGMP signaling in glucose transport is different between smooth muscle and skeletal muscle. Indeed, in rat skeletal muscle and mouse H-2K b muscle cells, 12 the increase in glucose transport is completely blocked by inhibition of NOS only under those conditions that lead to increased AMPK activity, and inhibitors of NOS have no effect on the increase in glucose transport caused by stimuli, such as insulin, that do not activate AMPK. Our data show that in human vascular smooth muscle, the increase in glucose transport is promoted by insulin via a NOS-and GC-dependent mechanism.
We next examined the contribution of PKG in the insulinand cGMP-stimulated glucose transport of hVSMCs. PKG regulates smooth muscle relaxation, platelet aggregation, cell growth, and differentiation (for review, see Pfeifer et al 38 ) . The expression of the type I PKG, and particularly the I␣ isoform, predominates in VSMCs 39 and decreases as VSMCs are passaged in vitro. 40 Our results show that in cultured hVSMCs, which express predominantly PKG I␣ (data not shown), the stimulating effects of insulin and cGMP on glucose transport require the cGMP-mediated PKG activation, as the pretreatment of hVSMCs with a selective inhibitor of PKG completely blocks the glucose uptake elicited by both insulin and 8-Br-cGMP. VASP, a protein expressed in vascular smooth muscle, is specifically phosphorylated at serine 239 by PKG. 28 Insulin elicits the NO/cGMP-dependent activation of PKG, as VASP phosphorylation at serine 239 is significantly increased by insulin, and this effect is almost completely abolished by the inhibition of sGC and PKG. So far, PKG plays a central role in the insulin-dependent rapid stimulation of glucose transport in hVSMCs, which occurs via the ability of insulin to promote the translocation of intracellular vesicles containing GLUT4 to the plasma membrane. This observation is of importance as in VSMCs, the molecular mechanisms of cGMP signaling distal to PKG I are not yet completely understood and are at present actively investigated. Several targets for PKG have been implicated in mediating the enzyme effects (for review, Pfeifer 38 ). It is assumed that at least part of the inhibitory responses mediated by PKG depends on the phosphorylation of the inositol triphosphate receptor and on the stimulation of the large conductance K-Ca channel. 38 Furthermore, vasorelaxation by NO/cGMP is also associated with an increase in the extent of phosphorylation of small proteins such as heat shock-related proteins that appear to be regulatory components of the actin-based cytoskeleton and seem to interact with intermediate filaments. 41 A functional role of the microtubule and actin cytoskeletal systems in the mechanism of insulin action on GLUT4 traffic is hypothesized. 4, 5 Indeed, GLUT4 translocation has been found to be sensitive to actin depolymerization, and disruption of actin microfilaments results in the localization of GLUT4 in larger, almost immobile vesicles in the juxtanuclear region. 42 Actin motors likely coordinate the interaction of GLUT4-enriched vesicles with microtubules, and both actin-based and microtubule-based motors are targets for PKG. 43 A very important role of PKG in insulininduced relaxation of VSMCs has been recently demonstrated. 44 The contractile effect of RhoA in VSMCs results from the activation of a Rho-dependent kinase, which phosphorylates the regulatory subunit of the myosin light chain phosphatase (MBP) and thereby inhibits the phosphatase activity. Insulin inhibits Rho signaling by decreasing RhoA translocation via the NO/cGMP/PKG signaling pathway to cause MBP activation via site-specific dephosphorylation of the regulatory subunit. PKG I␣ has also been shown to phosphorylate and inactivate RhoA, blocking Rho kinase-dependent inhibition of MBP in VSMCs. 44 Our results about the PKG dependence of the insulin-and cGMP-stimulated glucose transport (and even of the basal glucose transport) in hVSMCs indicate that the major role exerted by endogenous NO in both insulin-dependent relaxation/vasodilation and glucose uptake is mediated by PKG activation. Interestingly, pretreating cells with the PKG inhibitor resulted in a significant reduction of basal 2-deoxy-D-glucose transport, suggesting that PKG activity is needed for basal glucose transport. So far, physiopathological events in which NO has been shown to exert an effect have grown exponentially: such effects include now the insulinstimulated glucose transport in hVSMC.
